New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:34 EDTINSVInSite Vision, Senju Pharmaceutical announce collaboration agreement
InSite Vision Incorporated and Senju Pharmaceutical announced that they have entered into a collaboration and license agreement to develop and market InSite’s azithromycin ophthalmic solution using DuraSite including AzaSite 1% and AzaSite XtraTM 2% ocular antibiotics in Japan. Senju has agreed to pay InSite an upfront license fee, additional development milestones fees, and a percentage royalty on net sales.
News For INSV From The Last 14 Days
Check below for free stories on INSV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 16, 2014
08:35 EDTINSVInSite Vision issued U.S. patent covering Bromfenac formulations in DuraSite
InSite Vision Incorporated announced that the United States Patent and Trademark Office has issued a U.S. Patent No. 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite. The allowed patent contains both composition and method of treatment claims that will broadly cover all of InSite’s bromfenac product candidates, including BromSite for the treatment of inflammation and prevention of pain post cataract surgery. Additional bromfenac-containing products in InSite’s pipeline covered under this patent include: ISV-101 for the treatment of dry eye disease, back-of-the eye BromSite indications, such as the prevention of cystoid macular edema, as well as the combination of bromfenac and dexamethasone containing products such as BromDex. Due to USPTO delays, the patent term was extended by 155 days to provide protection for bromfenac formulations in DuraSite to August 2029.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use